TABLE 3.
General Health, Functional Status, and Lost Productivity in Individuals With and Without a History of Cancer
| Cancer | ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Breast (n = 825) | Prostate (n = 598) | Colorectal (n = 293) | Short Survival Cancersa (n = 193) | Multiple Cancers (n = 339) | Other Single Cancers (n = 2699) | No Cancer (n = 64,387) | Pb | |
| General health status | ||||||||
| Excellent/Very good | 51.2 (46.8–55.5) | 49.7 (44.6–54.9) | 49.8 (42.9–56.6) | 38.7 (30.4–47.8) | 38.6 (31.3–46.5) | 49.6 (47.3–51.9) | 60.0 (59.2–60.8) | <.0001 |
| Good | 31.4 (27.9–35.0) | 31.8 (27.1–37.0) | 28.7 (22.5–35.8) | 26.0 (19.0–34.4) | 26.9 (21.2–33.4) | 31.3 (29.1–33.6) | 26.2 (25.7–26.8) | |
| Fair/Poor | 17.5 (14.8–20.5) | 18.4 (15.6–21.6) | 21.5 (16.4–27.8) | 35.3 (27.0–44.5) | 34.5 (28.3–41.3) | 19.1 (17.4–20.9) | 13.7 (13.2–14.2) | |
| Functional status | ||||||||
| Limitation in physical functioning | 12.4 (10.3–14.8) | 11.9 (9.4–14.9) | 13.0 (9.8–17.0) | 20.5 (15.8–26.0) | 20.5 (16.2–25.5) | 16.3 (14.8–17.8) | 12.4 (11.8–13.0) | <.0001 |
| Limitation in physical functioning >3 mo | 10.6 (8.8–12.8) | 10.5 (8.1–13.5) | 12.4 (9.3–16.2) | 17.7 (13.7–22.6) | 18.9 (14.7–23.9) | 14.6 (13.3–16.0) | 11.1 (10.6–11.7) | <.0001 |
| Lost productivity | ||||||||
| Employed in past 12 months (age <65 y) | 81.6 (77.0–85.4) | 73.6 (62.8–82.2) | 79.2 (67.0–87.8) | 66.8 (52.0–78.9) | 57.1 (45.2–68.2) | 75.2 (72.3–77.9) | 81.4 (80.7–82.0) | <.0001 |
| Any limitation in work, housework, or school | 8.8 (7.1–11.0) | 9.4 (6.8–12.9) | 10.4 (7.6–14.1) | 17.5 (12.8–23.4) | 15.1 (11.5–19.7) | 12.5 (11.2–14.0) | 8.5 (8.0–9.0) | <.0001 |
| Completely unable to do activities | 4.7 (3.5–6.2) | 6.3 (4.4–9.1) | 7.4 (5.2–10.6) | 11.7 (8.3–16.4) | 10.3 (7.7–13.8) | 7.4 (6.3–8.6) | 5.2 (4.8–5.6) | <.0001 |
| Cognitive limitation | 3.4 (2.4–4.8) | 4.9 (3.5–6.9) | 4.6 (2.9–7.4) | 6.8 (4.5–10.1) | 8.5 (6.1–11.6) | 6.1 (5.1–7.2) | 4.4 (4.1–4.7) | <.0001 |
Data are presented as % (95% confidence interval). Predicted margins were determined using logistic regression models with age, comorbidities, race/ethnicity, and sex as covariates. Some sample sizes were smaller based on missing data on specific outcomes.
a
Cancers with <25% 5-year survival rate (liver, lung, pancreas, and stomach).
b
Wald test.